Several hereditary point mutations in human
apolipoprotein A-I (
apoA-I) have been associated with low
HDL-cholesterol levels and/or increased
coronary artery disease (CAD) risk. However, one
apoA-I mutation, the V19L, recently identified in Icelanders, has been associated with increased
HDL-cholesterol levels and decreased CAD risk. In an effort to gain mechanistic insight linking the presence of this mutation in
apoA-I with the increase of
HDL-cholesterol levels we evaluated the effect of V19L mutation on the conformational integrity and functional properties of
apoA-I in
lipid-free and lipidated form.
ApoA-I[V19L] was found to be thermodynamically destabilized in
lipid-free form and displays an increased capacity to associate with
phospholipids compared to WT
apoA-I. When associated to reconstituted HDL (rHDL),
apoA-I[V19L] was more thermodynamically stabilized than WT
apoA-I.
ApoA-I[V19L] displayed normal capacity to promote ABCA1-mediated
cholesterol efflux and to activate the
enzyme LCAT, in
lipid-free and rHDL-associated forms, respectively. Additionally, rHDL-associated
apoA-I[V19L] showed normal capacity to promote ABCG1-mediated
cholesterol efflux, but 45% increased capacity to promote SR-BI-mediated
cholesterol efflux, while the SR-BI-mediated HDL-
lipid uptake was normal. Overall, our findings show that the
apoA-I V19L mutation does not affect the first steps of HDL biogenesis pathway. However, the increased capacity of
apoA-I[V19L] to associate with
phospholipids, in combination with the enhanced thermodynamic stability of
lipoprotein-associated
apoA-I[V19L] and increased capacity of
apoA-I[V19L]-containing
lipoprotein particles to accept additional
cholesterol by SR-BI could account for the increased
HDL-cholesterol levels observed in human carriers of the mutation.